8-K ·Filed Aug 14, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
This is a minor positive milestone indicating trial progression, but no data readout or financial impact is disclosed. Monitor for future enrollment updates and interim data, which could provide more meaningful catalysts.
Latest settled — T+20d
CLYM ▼ -10.84% at T+20d
NEUTRAL call -10.84% · α vs SPY -8.85% · entry $16.33 → $14.56
Latest observation: T+49 -39.77% FF3 residual α
T+1d
+6.80%
call +6.80% · α +7.27%
$17.44
settled 2mo ago
T+5d
+5.82%
call +5.82% · α +7.19%
$17.28
settled 2mo ago
T+20d
-10.84%
call -10.84% · α -8.85%
$14.56
settled 6w ago
T+60d
Pending
in 14d
Price Chart
Loading chart...
Executive Summary
Climb Bio announced that the first patient has been dosed in a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in China, conducted in collaboration with Beijing Mabworks Biotech. This is a routine clinical milestone with no financial data or material terms disclosed.
Key Facts
- First patient dosed in Phase 2 trial for IgAN in China
- Trial conducted in collaboration with Beijing Mabworks Biotech Co., Ltd.
- No financial terms, data, or guidance provided in the filing
Financial Impact
Not specified
Risk Factors
- Clinical trial failure or delay
- Collaboration execution risk
- Regulatory uncertainty in China
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-350596 |
| Document: 0001193125-26-350596-index-headers.html | 0001193125-26-350596 |
| Document: 0001193125-26-350596-index.html | 0001193125-26-350596 |
| Document: 0001193125-26-350596.txt | 0001193125-26-350596 |
20 reports for CLYM
80% Hit rate @ T+1 Went positive at some point 4 of 5 best @ T+1▲ +6.79%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+1 | — | — |
Oct 23, 2026 2d ago | 8-K | $10.47 | awaiting T+1 | — | $9.36 (−10.62%) |
Oct 23, 2026 2d ago | Press Release | $10.34 | awaiting T+1 | — | $9.36 (−9.50%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $9.36 (−34.15%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $9.36 (−35.86%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $9.36 (−42.70%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $9.36 (−33.16%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $9.36 (−29.59%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.36 (+18.56%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.36 (+18.56%) |
Showing 10 of 20
US Market Status
Market Open — Closes in 3h 28m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers